Patent SG-11201909859R-A (SG)
Title: Platinum-resistant cancer treatment
Inventor: BANERJI UDAI
IPC: A61K31/517
Filed: 2018-05-16
Abstract: WO 18/ 211433 Al 160 140 120 100 80 tu \": 60 40 § 20 0 Er' -20 0 - -40 -60 -80 -100 U U Fig. 4 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 November 2018 (22.11.2018) WIPO I PCT Iiiimmoilloiollmonoloololololomiinooluom (10) International Publication Number WO 2018/211433 Al (51) International Patent Classification: A61K 31/517 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/IB2018/053428 (22) International Filing Date: 16 May 2018 (16.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1707864.3 16 May 2017 (16.05.2017) GB 62/513,627 01 June 2017 (01.06.2017) US (71) Applicant: BTG INTERNATIONAL LIMITED [GB/GB]; 5 Fleet Place, London EC4M 7RD (GB). (72) Inventor: BANERJI, Udai; The Drug Development Unit, The Institute of Cancer Research and The Royal Marsden, Sycamore House, Downs Road, Sutton Surrey SM2 5PT (GB). (74) Agent: DOLAN, Anthony, Patrick; BTG International Limited, 5 Fleet Place, London Greater London EC4M 7RD (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: PLATINUM-RESISTANT CANCER TREATMENT (57) : A compound of formula I or a pharmaceutically ac- ceptable salt or ester thereof is provided for the treatment of cancer wherein (i) the cancer is one that has the characteristic of being a type prone to being or becoming refractory or resistant to platinum drug based therapy and (ii) the treatment is with a dose of between lmg/m 2 and 30mg/m 2 of compound per patient body surface area per adminis- tration. Method of treatment and novel dosage forms are also provid- ed. Particularly treated are ovarian cancers, particularly those express- ing a-folate receptors, including epithelial ovarian, fallopian tube or peritoneal cancer. [Continued on next page] WO 2018/211433 Al MIDEDIMOMMIONEIEHI110101EMMOVOIMIE Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))